Vertically Integrated Healthcare Model

Medpal AI

10/02/2026 07:00

RNS Number : 3270S

Medpal AI PLC

10 February 2026

 

10 February 2026

MedPal AI plc

("MedPal AI" or the "Company")

Operational Update: Vertically Integrated UK Healthcare Platform and Multi-Channel Revenue Model

MedPal AI plc (AIM: MPAL | Frankfurt: Z1N), the AI-powered digital health and pharmacy services provider, provides this update on its UK vertically integrated platform. After seizing the opportunity to establish the MedPal Limited pharmacy operations in October 2025, the Company's strategy has evolved from being centred on the MedPal app to integrating it with an AI driven triage system and prescribing service.

The Company's business model uniquely links AI-assisted digital health to regulated pharmacy and clinical services, generating revenue at every patient interaction. This creates strong unit economics that improve with scale

Highlights

·      Vertically integrated UK platform is fully operational, merging AI-powered digital health with human-validated prescribing and robotic pharmacy dispensing/delivery.

·      Multi-revenue per patient: app subscriptions £3.99/month or £29.99/year, NHS dispensing fees £9.90+ per item, private prescription income, and clinical consultation fees.

·      Diverse customer acquisition channels: NHS contracts, DSP licences, direct ads via MedPal.clinic and app, plus Epassi partnership accessing 11m+ employees.

·      Bi-directional cross-sell: App users convert to pharmacy patients; pharmacy patients to app subscribers, boosting lifetime value.

·      Scale demonstrated: 36,951 items dispensed in January 2026; 7,791 app installs, all paid or on Epassi acquisition pathway (no free tier).

 

Integrated Model and Revenue Streams

Core to operations is human-in-the-loop prescribing: AI triage is validated by professionals, followed by robotic dispensing and delivery. Each patient potentially yields multiple revenues: recurring app subscriptions , NHS dispensing fees, private prescriptions (e.g., GLP-1 treatments), and consultation fees. 36,951prescription items were dispensed in January, highlighting revenue potential.

Patient Acquisition Channels

Patient growth draws from multiple independent sources for resilience: NHS/DSP contracts for stable volume; direct ads and MedPal.clinic for private services; the MedPal app with 7,791 installs (either paid or Epassi-linked); and Epassi partnerships reaching 11m+ employees, where complimentary access converts to subscriptions while generating pharmacy revenue.

 

Jason Drummond, CEO of MedPal AI, said:

"MedPal AI's platform uniquely integrates AI, clinicians, and robotic dispensing for end-to-end care and revenue at every step. Diverse channels-from NHS contracts to Epassi's 11m+ employees fuel resilient growth. Our cross-sell flywheel compounds value: app users become pharmacy patients, and vice versa. With 36,951 items dispensed in January and 7,791 app installs, we are well positioned for sustained expansion."

 

Enquiries:

MedPal AI plc
Jason Drummond, Chief Executive Officer
Via Square1 Consulting
Cairn Financial Advisers LLP
Louise O'Driscoll/Jo Turner
+44 (0) 20 7213 0880
Clear Capital Markets Limited
Bob Roberts
+44 (0) 20 3869 6080
Square1 Consulting
David Bick
+44 (0) 20 7929 5599
+44 (0) 7831 381201

 

 

 

About MedPal AI

MedPal AI is a UK-based digital health company specialising in AI-driven wellness management. Its core app aggregates data from over 100 wearables and health apps (e.g. Apple Health, Fitbit, Garmin) into a unified profile, offering non-clinical, personalised lifestyle guidance through its AI wellness coach. The Company is also developing conversational AI to provide voice-based, real-time health insights, alerts, and recommendations.

Through its wholly owned subsidiary MedPal Limited, the Company operates a 24/7 AI-powered automated pharmacy distribution centre, providing nationwide NHS and private prescription services. The facility leverages advanced robotic dispensing technology integrated with AI triage to deliver rapid, cost-effective medication fulfilment with same-day and next-day delivery capabilities.

MedPal AI has a partnership agreement with Epassi UK Limited, which will, for a limited time, grant exclusive, zero-cost access to the MedPal AI app across Epassi's network of 11M+ employees at major firms like Siemens and Volvo. Beyond consumers, MedPal AI plans to expand via B2B licensing to healthcare providers, businesses, and insurers, with potential use in insurance-linked wellness programs to reduce premiums and drive new revenue through institutional partnerships. The Company also has a partnership agreement with Independent Gyms Ltd.

Forward Looking Statements

This announcement contains forward-looking statements relating to expected or anticipated future events and anticipated results that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties, such as general economic, market and business conditions, competition for qualified staff, the regulatory process and actions, technical issues, new legislation, uncertainties resulting from potential delays or changes in plans, uncertainties resulting from working in a new political jurisdiction, uncertainties regarding the results of exploration, uncertainties regarding the timing and granting of prospecting rights, uncertainties regarding the timing and granting of regulatory and other third party consents and approvals, uncertainties regarding the Company's or any third party's ability to execute and implement future plans, and the occurrence of unexpected events.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
STRUKVURNOUURUR